Table 3.

Anti-TNF-α agents for inflammatory bowel disease

Preparation	Drug	Route of administration	Target disease	Induction dose	Maintenance dose
Infliximab	Remicade	Intravenous	UC, CD	5 mg/kg at weeks 0, 2, and 6	5 mg/kg every 8 weeks
	Remsima (CT-P13)	Intravenous	UC, CD	5 mg/kg at weeks 0, 2, and 6	5 mg/kg every 8 weeks
		Subcutaneous	UC, CD	5 mg/kg at weeks 0, 2 (IV) 120 mg at week 6 (SC)	120 mg every 2 weeks
	Remaloce (SB2)	Intravenous	UC, CD	5 mg/kg at weeks 0, 2, and 6	5 mg/kg every 8 weeks
Adalimumab	Humira	Subcutaneous (citrate-free formulation)	UC, CD	160 mg at week 0 80 mg at week 2 40 mg at week 4	40 mg every other week
	Adalloce (SB5)	Subcutaneous	UC, CD	160 mg at week 0 80 mg at week 2 40 mg at week 4	40 mg every other week
	Yuflyma (CT-P17)	Subcutaneous (citrate-free formulation)	UC, CD	160 mg at week 0 80 mg at week 2 40 mg at week 4	40 mg every other week
Golimumab	Simponi	Subcutaneous	UC	200 mg at week 0 100 mg at week 2 50 mg at week 6 (100 mg if weight > 80 kg)	50 mg (or 100 mg) every 4 weeks

TNF-α, tumor necrosis factor-α; UC, ulcerative colitis; CD, Crohn’s disease; IV, intravenous; SC, subcutaneous.